Viridian Therapeutics' experimental treatment for chronic thyroid eye disease (TED) significantly reduced symptoms such as double vision and eye bulging in a late-stage study, sending its shares ...

Viridian Therapeutics said on Tuesday its experimental treatment helped significantly reduce symptoms of thyroid eye disease (TED) in a late-stage study, setting the stage to become the first ...

Shares of Viridian Therapeutics (VRDN-5.13%) were down more 14% as of 11:40 a.m. on Tuesday after the company announced preliminary results from a phase 2 trial for a chronic thyroid eye disease ...

Shares of Viridian Therapeutics Inc. VRDN fell in the extended session Monday after the biotech drug maker said it was making changes to its study design for a chronic thyroid eye disease therapy ...

Viridian said this week that it is on track to report the phase 3 results from REVEAL-1 and REVEAL-2 trials of VRDN-003 in active and chronic TED patients in the first half of 2026, and I believe ...

The flagship drug brought over from legacy Viridian is VRDN-001, a treatment for bulging eyes caused by Graves’ Disease or other ocular problems caused by an overactive thyroid.

Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2 ...

Summary. Viridian was one of my top picks in 2022 and it made the 2023 list again. VRDN-001 data continue to impress and Viridian looks well-positioned to disrupt the thyroid eye disease market ...

Viridian’s candidate surprisingly showed more significant declines in proptosis in the 3 mg/kg group compared to the larger 10 mg/kg, with six patients reporting an average decline from baseline ...

Viridian Therapeutics’ phase 3 thyroid eye disease (TED) clinical trial has hit its primary and secondary endpoints. But with Amgen’s Tepezza already on the market, the data leave scope to ...

Viridian plans to initiate the THRIVE-2 Phase 3 trial to evaluate the safety and efficacy of VRDN-001 in patients with chronic TED in Q3 2023, with topline data expected by the end of 2024.